CA2385665A1 - Modulation of enos activity and therapeutic uses thereof - Google Patents

Modulation of enos activity and therapeutic uses thereof Download PDF

Info

Publication number
CA2385665A1
CA2385665A1 CA002385665A CA2385665A CA2385665A1 CA 2385665 A1 CA2385665 A1 CA 2385665A1 CA 002385665 A CA002385665 A CA 002385665A CA 2385665 A CA2385665 A CA 2385665A CA 2385665 A1 CA2385665 A1 CA 2385665A1
Authority
CA
Canada
Prior art keywords
vegf
enos
receptor
kdr
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002385665A
Other languages
English (en)
French (fr)
Inventor
Ben-Quan Shen
Thomas Zioncheck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2385665A1 publication Critical patent/CA2385665A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002385665A 1999-11-02 2000-11-02 Modulation of enos activity and therapeutic uses thereof Abandoned CA2385665A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16313299P 1999-11-02 1999-11-02
US60/163,132 1999-11-02
PCT/US2000/030294 WO2001032695A2 (en) 1999-11-02 2000-11-02 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF

Publications (1)

Publication Number Publication Date
CA2385665A1 true CA2385665A1 (en) 2001-05-10

Family

ID=22588624

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002385665A Abandoned CA2385665A1 (en) 1999-11-02 2000-11-02 Modulation of enos activity and therapeutic uses thereof

Country Status (6)

Country Link
EP (1) EP1225910A2 (ja)
JP (1) JP2003513105A (ja)
AU (1) AU782158B2 (ja)
CA (1) CA2385665A1 (ja)
IL (1) IL148674A0 (ja)
WO (1) WO2001032695A2 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007110847A (ru) * 2004-08-20 2008-09-27 Де Джонс Хопкинс Юниверсити (US) Способы лечения ангиогенеза
US8927511B2 (en) * 2008-12-04 2015-01-06 Curna, Inc. Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
ATE287271T1 (de) * 1996-11-01 2005-02-15 Ark Therapeutics Ltd Verwendung von vegf zur herstellung eines medikaments zur behandlung oder verhinderung der intimalen hyperplasie und verabreichungsgerät
DE69915310T2 (de) * 1998-09-09 2005-03-10 Scios Inc., Fremont Methoden zur behandlung der salzabhängigen hypertonie
CA2370246C (en) * 1999-04-16 2017-03-21 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof
CA2373822A1 (en) * 1999-05-20 2000-11-30 Scios Inc. Vascular endothelial growth factor variants

Also Published As

Publication number Publication date
WO2001032695A2 (en) 2001-05-10
EP1225910A2 (en) 2002-07-31
IL148674A0 (en) 2002-09-12
JP2003513105A (ja) 2003-04-08
AU1756501A (en) 2001-05-14
WO2001032695A3 (en) 2002-02-14
AU782158B2 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
US6750044B1 (en) Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
US20060063203A1 (en) Vascular endothelial cell growth factor variants and uses thereof
US7045133B2 (en) VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
EP0851920B1 (en) Variants of vascular endothelial cell growth factor, their uses, and processes for their porduction
Rauly et al. Induction of a negative autocrine loop by expression of sst2 somatostatin receptor in NIH 3T3 cells.
US20060188503A1 (en) Modulation of eNOS activity and therapeutic uses thereof
AU782158B2 (en) Modulation of eNOS activity and therapeutic uses thereof
US20060269997A1 (en) Vascular endothelial cell growth factor variants and uses thereof
RU2392963C2 (ru) Синтетические варианты гипергликозилированного протеазо-резистентного полипептида, пероральные композиции и способы применения таких вариантов
JP2001500384A (ja) 変化した薬理学的特性を持つ血管内皮細胞増殖因子の変異体とその関連態様
CN116234541A (zh) 通过EpoR拮抗剂治疗疾病
AU2004202596B2 (en) Vascular endothelial cell growth factor variants and uses thereof
CN101070343A (zh) 血管内皮细胞生长因子变体及其应用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued